业绩总结 - Rezdiffra在2024年第三季度的净销售额为6220万美元[22] - 运营损失为1.163亿美元，较2023年同期的9850万美元有所增加[22] - 销售、一般和行政费用（SG&A）为1.076亿美元，较2023年同期的2760万美元显著增加[22] - 研发费用为6870万美元，较2023年同期的7100万美元有所下降[22] 用户数据 - 超过6800名患者正在使用Rezdiffra，覆盖率超过80%的商业保险人群[21] - 超过95%的医疗保险接受非侵入性测试（NIT），而不需要活检[21] - 在主要目标医生中，约40%的医生开具了Rezdiffra处方[21] 未来展望 - MAESTRO-NASH OUTCOMES试验已完成入组，预计将为Rezdiffra在肝硬化NASH中的首次批准提供支持[20] - 欧盟市场的上市计划按计划推进，预计在2025年下半年获得EMA批准[20] 现金状况 - 截至2024年9月30日，公司现金及现金等价物、受限现金和可交易证券总额为10亿美元[22]

财务表现 - 2021年第四季度收入为1.33亿美元，同比增长17%[1] - 2021年全年收入为4.85亿美元，同比增长22%[1] - 2021年第四季度毛利率为82.5%，同比提高1.5个百分点[1] - 2021年全年毛利率为82.1%，同比提高1.1个百分点[1] 业务发展 - 2021年第四季度新增付费用户数为10.4万，同比增长19%[1] - 2021年全年新增付费用户数为41.5万，同比增长23%[1] - 截至2021年12月31日，总付费用户数达到1,050万[1] - 2021年第四季度付费用户转化率为4.4%，同比提高0.4个百分点[1] - 2021年全年付费用户转化率为4.3%，同比提高0.4个百分点[1] 产品创新 - 2021年第四季度推出了新的AI写作助手产品[1] - 2021年全年持续推出新功能和产品升级[1] - 不断优化产品体验，提高用户满意度[1] 未来展望 - 2022年全年收入预计增长20%-25%[1] - 将继续投资于产品创新和用户增长[1] - 保持高毛利率水平[1]

CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced multiple resmetirom data presentations at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting, taking place from November 15-19, 2024 in San Diego. Bill Sibold, Chief Executive Officer of Madriga ...

文章核心观点 - Madrigal Pharmaceuticals是一家专注于开发创新疗法的生物制药公司,其主要产品候选药物Rezdiffra引起了分析师的关注 [1] - 分析师之前一直对该公司的估值过高存在担忧,因此一直未建立头寸 [1] 公司概况 - Madrigal Pharmaceuticals是一家专注于开发创新疗法的生物制药公司 [1] - 其主要产品候选药物为Rezdiffra [1] 行业分析 - 分析师对Madrigal Pharmaceuticals的主要产品候选药物Rezdiffra持关注态度 [1] - 分析师之前一直对该公司的估值过高存在担忧,因此一直未建立头寸 [1]

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH cirrhosis, a population at high risk of progressing to adverse liver-related outcomesStudy may also support full approval of RezdiffraTM (resmetirom) in noncirrhotic NASH CONSHOHOCKEN, Pa., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis ...

CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets. Following the announcement, Madrigal's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals webs ...

CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Investor Conference at 2:00 P.M. ET on Monday, Oct. 7, 2024. The fireside chat will be webcast live and may be accessed here or by visiting Madrigal's website's Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Madrigal Pharmaceut ...

It has been about a month since the last earnings report for Madrigal (MDGL) . Shares have added about 1% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Madrigal due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Madrigal Q2 Earnings Top, NASH Drug Drives Top Lin ...

Global Research and Evidence Lab 14 August 2024 Madrigal Pharmaceuticals Inc Rezdiffra Formulary Coverage Tracker Rezdiffra coverage substantially improves in July update (50% commercial coverage, consistent w/mgmt commentary). See inside for an overview of the data on coverage and formulary status plan by plan and how Rezdiffra coverage is changing over time. We update our proprietary monthly formulary coverage tracker for MDGL's Rezdiffra using Evidence Lab's US drug formulary monitor (access data here). ...

One player's minor pain is another's moderate gain. It's not often that a biotech wins when a big pharma stumbles, but Madrigal Pharmaceuticals (MDGL 0.64%) is now in a better place than before because of a setback at Danish drug giant Novo Nordisk (NVO 2.83%). The two cardiometabolic drug developers will avoid direct competition for the time being, and now, any head-tohead match up in the future could favor Madrigal a bit more than before. But is the biotech still a buy? Let's clarify the question by looki ...